NanoFCM develops advanced analytical instruments that enable scientists to study nanoparticles used in areas including gene therapy, vaccines, extracellular vesicles and targeted drug delivery. Its technology helps researchers better understand particles that are too small to be analysed using many conventional laboratory techniques, supporting the development of more precise and effective treatments.

The company’s systems are used in research linked to diseases including cancer, neurological conditions and rare genetic disorders, as well as in the development of next-generation vaccines and cell and gene therapies.

NanoFCM’s EMEA operations are based at Stevenage Bioscience Catalyst, supporting customers across Europe, the Middle East and Africa.